SA518400463B1 - عمليات لتحضير أوليجومرات فوسفوروداي أميدات مورفولينو - Google Patents

عمليات لتحضير أوليجومرات فوسفوروداي أميدات مورفولينو

Info

Publication number
SA518400463B1
SA518400463B1 SA518400463A SA518400463A SA518400463B1 SA 518400463 B1 SA518400463 B1 SA 518400463B1 SA 518400463 A SA518400463 A SA 518400463A SA 518400463 A SA518400463 A SA 518400463A SA 518400463 B1 SA518400463 B1 SA 518400463B1
Authority
SA
Saudi Arabia
Prior art keywords
processes
morpholino oligomers
phosphorodiamidate morpholino
preparing
oligomer
Prior art date
Application number
SA518400463A
Other languages
English (en)
Inventor
كاي باو
شيمابوكو روس
توماس كاتي
مارتيني ميتشيل
Original Assignee
ساريبتا ثيرابيوتكس، انك
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2017/040311 external-priority patent/WO2017205879A2/en
Application filed by ساريبتا ثيرابيوتكس، انك filed Critical ساريبتا ثيرابيوتكس، انك
Publication of SA518400463B1 publication Critical patent/SA518400463B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • C08G81/02—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers at least one of the polymers being obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • C08G81/024—Block or graft polymers containing sequences of polymers of C08C or C08F and of polymers of C08G
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/333—Modified A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/336—Modified G
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

يتعلق الاختراع الحالي بعمليات لتحضير أوليجومرoligomer (على سبيل المثال، أوليجومر مورفولينو morpholino oligomer ). قد تكون العمليات التخليقية الموصوفة هنا مميزة في زيادة تخليق الأوليجومرات scaling up oligomer بينما تحافظ على الناتج yield والنقاء purity الإجماليين للأوليجومر الذي تم تخليقه. شكل 1.
SA518400463A 2016-05-24 2018-11-19 عمليات لتحضير أوليجومرات فوسفوروداي أميدات مورفولينو SA518400463B1 (ar)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662340953P 2016-05-24 2016-05-24
US201662341049P 2016-05-24 2016-05-24
US201662357153P 2016-06-30 2016-06-30
US201662357134P 2016-06-30 2016-06-30
US201762508256P 2017-05-18 2017-05-18
PCT/US2017/040311 WO2017205879A2 (en) 2016-05-24 2017-06-30 Processes for preparing phosphorodiamidate morpholino oligomers

Publications (1)

Publication Number Publication Date
SA518400463B1 true SA518400463B1 (ar) 2022-01-10

Family

ID=66624310

Family Applications (1)

Application Number Title Priority Date Filing Date
SA518400463A SA518400463B1 (ar) 2016-05-24 2018-11-19 عمليات لتحضير أوليجومرات فوسفوروداي أميدات مورفولينو

Country Status (6)

Country Link
US (2) US10947533B2 (ar)
BR (1) BR112018074330B1 (ar)
IL (1) IL263052B (ar)
MA (1) MA45362A (ar)
SA (1) SA518400463B1 (ar)
SG (1) SG10202101834QA (ar)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
MA45155A (fr) * 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
MA45362A (fr) * 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
JP7008642B2 (ja) 2016-05-24 2022-01-25 サレプタ セラピューティクス， インコーポレイテッド オリゴマー調製のためのプロセス

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
EP0215942B1 (en) 1985-03-15 1995-07-12 Antivirals Inc. Polynucleotide assay reagent and method
WO1990002749A1 (en) 1988-09-01 1990-03-22 Forskningscenter Risø Peptide synthesis method and solid support for use in the method
US5773530A (en) 1993-12-29 1998-06-30 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine adenosine antagonists
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
PT1178999E (pt) 1999-05-04 2007-06-26 Santaris Pharma As Análogos de l-ribo-lna
US6784291B2 (en) 2000-05-04 2004-08-31 Avi Biopharma, Inc. Splice-region antisense composition and method
JP2005514005A (ja) 2001-09-04 2005-05-19 エクシコン エ／エス 新規のｌｎａ組成物およびその使用
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
CA2504554A1 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. 2'-substituted oligomeric compounds and compositions for use in gene modulations
US7759513B2 (en) 2003-02-21 2010-07-20 Nigu Chemie Gmbh Photolabile protective groups for improved processes to prepare oligonucleotide arrays
SI1766010T1 (sl) 2004-06-28 2011-06-30 Univ Western Australia Protismiselni oligonukleotidi za induciranje preskakovanja eksonov in postopki za njihovo uporabo
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US9371348B2 (en) 2006-11-27 2016-06-21 The Trustees Of The University Of Pennsylvania Photocleavable oligonucleotide and uses thereof
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
MX2010004955A (es) 2007-11-15 2010-06-30 Avi Biopharma Inc Metodo de sintesis de oligomeros de morfolina.
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
JP2012523225A (ja) 2009-04-10 2012-10-04 アソシアシオン・アンスティテュ・ドゥ・ミオロジー 疾患の処置のためのトリシクロ−ｄｎａアンチセンスオリゴヌクレオチド、組成物及び方法
PL2499249T3 (pl) 2009-11-12 2019-03-29 Univ Western Australia Cząsteczki antysensowne i sposoby leczenia patologii
WO2011150408A2 (en) 2010-05-28 2011-12-01 Avi Biopharma, Inc. Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
JP5831455B2 (ja) 2010-09-30 2015-12-09 日本新薬株式会社 モルホリノ核酸誘導体
WO2013026142A1 (en) 2011-08-23 2013-02-28 The Royal Institution For The Advancement Of Learning/Mcgill University Ionic tags for synthesis of oligoribonucleotides
EP2581448B1 (en) 2011-10-13 2015-01-28 Association Institut de Myologie Tricyclo-phosphorothioate DNA
US9278987B2 (en) 2011-11-18 2016-03-08 Sarepta Therapeutics, Inc. Functionally-modified oligonucleotides and subunits thereof
JP6496549B2 (ja) 2011-11-30 2019-04-03 サレプタ セラピューティクス， インコーポレイテッド 脊髄性筋萎縮症における誘発されたエクソン包含
WO2013128281A1 (en) 2012-02-28 2013-09-06 Population Genetics Technologies Ltd Method for attaching a counter sequence to a nucleic acid sample
PT2970964T (pt) * 2013-03-14 2019-03-14 Sarepta Therapeutics Inc Composições de skipping de exões para o tratamento da distrofia muscular
EP3662912A1 (en) 2013-03-15 2020-06-10 Sarepta Therapeutics, Inc. Improved dosages of eteplirsen for treating duchenne muscular dystrophy
EP3015467A4 (en) 2013-05-24 2016-11-02 Ajinomoto Kk PROCESS FOR THE PRODUCTION OF MORPHOLINO-OLIGONUCLEOTIDE
BR112018074340A2 (pt) 2016-05-24 2019-03-06 Sarepta Therapeutics, Inc. processos para preparar oligômeros morfolino fosforodiamidato
JP7008642B2 (ja) 2016-05-24 2022-01-25 サレプタ セラピューティクス， インコーポレイテッド オリゴマー調製のためのプロセス
US11472824B2 (en) * 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
MA45362A (fr) * 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
MA45155A (fr) * 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
BR112019012651A2 (pt) 2016-12-19 2020-01-28 Sarepta Therapeutics Inc conjugados de oligômero de salto de éxon para distrofia muscular

Also Published As

Publication number Publication date
US20220112491A1 (en) 2022-04-14
BR112018074330A2 (pt) 2019-10-01
BR112018074330B1 (pt) 2023-02-07
MA45362A (fr) 2019-04-10
IL263052A (en) 2018-12-31
US10947533B2 (en) 2021-03-16
IL263052B (en) 2021-12-01
US20200080079A1 (en) 2020-03-12
SG10202101834QA (en) 2021-04-29

Similar Documents

Publication Publication Date Title
SA518400462B1 (ar) عمليات لتحضير أوليجومرات فوسفوروداي أميدات مورفولينو
MX2018014123A (es) Procesos para preparar oligomeros de morfolino fosforodiamidato.
SA518400500B1 (ar) عمليات لتحضير أوليجومرات
SA518400463B1 (ar) عمليات لتحضير أوليجومرات فوسفوروداي أميدات مورفولينو
MX2018014160A (es) Procesos para preparar oligomeros de morfolino fosforodiamidato.
MX2019000664A (es) Preparacion de 14-metil-16-oxabiciclo[10.3.1]pentadecenos de 3-metil-1,5 ciclopentadecanediona.
SA518391776B1 (ar) تخليق انتقائي مزدوج التجاسم لمشتقات الفوسفات
MY193158A (en) Continuous processes for the highly selective conversion of aldohexose-yielding carbohydrate to ethylene glycol
WO2016207914A3 (en) Methods for preparing oltipraz
WO2016033437A3 (en) Polyethers, polyamines, polythioethers, and methods for making same
WO2017112809A8 (en) System and method for solution phase gap peptide synthesis
TW201613953A (en) Process for the preparation of cyclic depsipeptides
NZ720106A (en) A process for the preparation of regadenoson
MX2016016479A (es) Metodo para producir un pentapeptido sintetico.
NZ725496A (en) Cycloalkyl-linked diheterocycle derivatives
MX2018009847A (es) Metodo para preparar derivado de polietilenglicol-dialdehido.
MX2020007646A (es) Procesos para la sintesis de sulfentrazona.
EP3672601A4 (en) PROCESS FOR THE PRODUCTION OF PHOSPHORDIAMIDATE-MORPHOLINE OLIGOMERS BY FAST FLOW SYNTHESIS
MX2022001549A (es) Nuevas sintesis telescopicas de 2-metoximetil-p-fenilendiamina.
WO2016079757A3 (en) NOVEL PROCESSES FOR THE PREPARATION OF SUBSTITUTED 5-HYDROXYMETHYL-OXAZOLIDINE-2-ONE
MX2016011955A (es) Proceso de preparacion de derivados de 3,5-bis(haloalquil)pirazol a partir de a,a-dihaloaminas y cetiminas.
MX2015015720A (es) Proceso para preparar derivados de 3, 5-bis (fluoroalquil) pirazol a partir de a, a-dihaloaminas.
NZ759608A (en) Process for the preparation of (s,s)-secoisolariciresinol diglucoside and (r,r)-secoisolariciresinol diglucoside
EP3974419A3 (en) Nebivolol synthesis method and intermediate compound thereof
MX2017016161A (es) Nuevo proceso de sintesis de diazoxida.